<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00945802</url>
  </required_header>
  <id_info>
    <org_study_id>FST201-AOE-02</org_study_id>
    <nct_id>NCT00945802</nct_id>
  </id_info>
  <brief_title>FST-201 In The Treatment of Acute Otitis Externa</brief_title>
  <official_title>A Multi-Center, Randomized, Double-Masked Clinical Study Evaluating the Efficacy Of FST-201 (Dexamethasone 0.1%) Otic Suspension (Foresight Biotherapeutics, Inc.) Vs. Ciprodex (Ciprofloxacin 0.3%, Dexamethasone 0.1%) Otic Suspension (Alcon Laboratories, Inc.) in Subjects With Acute Otitis Externa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the efficacy of FST-201 compared to Ciprodex in&#xD;
      the treatment of acute otitis externa. This trial is designed to enable filing of a New Drug&#xD;
      Application in support of FST-201 for the indication of acute otitis externa.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">July 31, 2009</start_date>
  <completion_date type="Actual">July 31, 2010</completion_date>
  <primary_completion_date type="Actual">July 31, 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall clinical cure as defined by absence of the signs and symptoms of AOE including ear inflammation, edema, tenderness and otic discharge.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Microbiological resolution defined as elimination of pre-treatment pathogenic bacteria.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Acute Otitis Externa</condition>
  <arm_group>
    <arm_group_label>FST-201 (dexamethasone 0.1%) Otic Suspension</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ciprofloxacin 0.3%, dexamethasone 0.1%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FST-201 (dexamethasone 0.1%) Otic Suspension</intervention_name>
    <description>Instill four drops two times a day</description>
    <arm_group_label>FST-201 (dexamethasone 0.1%) Otic Suspension</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ciprofloxacin 0.3%, dexamethasone 0.1%</intervention_name>
    <description>Instill four drops two times a day</description>
    <arm_group_label>ciprofloxacin 0.3%, dexamethasone 0.1%</arm_group_label>
    <other_name>Ciprodex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have a clinical diagnosis of AOE in one or both ears, defined as a clinical score of&#xD;
             at least 1 for edema (0-3 scale), 2 for overall inflammation (0-3 scale) and 1 for&#xD;
             tenderness (absent=0, present=1).&#xD;
&#xD;
          -  Be at least 18 years of age at Visit 1 (Day 1, Screening/Baseline) of either sex and&#xD;
             any race.&#xD;
&#xD;
          -  Provide written informed consent or parental assent.&#xD;
&#xD;
          -  Be willing and able to follow all instructions and attend all study visits&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        All subjects must not:&#xD;
&#xD;
          -  Have known sensitivity to any component of the study medications&#xD;
&#xD;
          -  Have a current infection requiring systemic antimicrobial treatment&#xD;
&#xD;
          -  Have used topical or systemic pain meds on the same day as Screening/Baseline Visit 1&#xD;
             and for the duration of the study.&#xD;
&#xD;
          -  Take any systemic (within 30 days) or otic corticosteroids (within 1 days) prior to&#xD;
             Screening/Baseline Visit 1&#xD;
&#xD;
          -  Current use of topical or systemic non-steroidal or other anti-inflammatory drugs.&#xD;
&#xD;
          -  Use any topical otic treatment with alcohol, vinegar, hydrogen peroxide or other&#xD;
             astringent medication during the course of the study or on the same day as&#xD;
             Screening/Baseline Visit 1&#xD;
&#xD;
          -  Have taken any antibiotics within 3 days prior to Visit 1&#xD;
&#xD;
          -  Have signs and symptoms of AOE for &gt; 4 weeks at Screening/Baseline Visit 1&#xD;
&#xD;
          -  Have a non-intact or perforated tympanic membrane in the enrolled ear&#xD;
&#xD;
          -  Have a clinical diagnosis of chronic suppurative otitis media, acute otitis media or&#xD;
             acute otorrhea in patients with tympanostomy tubes&#xD;
&#xD;
          -  Have a clinical diagnosis of malignant otitis externa&#xD;
&#xD;
          -  Have overt fungal AOE&#xD;
&#xD;
          -  Have a viral infection of the pinna or tympanic membrane (i.e herpes zoster)&#xD;
&#xD;
          -  Have congenital abnormalities of the external auditory canal in the enrolled ear(s)&#xD;
&#xD;
          -  Have obstructive bony exostoses in the enrolled ear(s)&#xD;
&#xD;
          -  Have mastoid or other suppurative, non-infectious ear disorders (e.g, cholesteatoma)&#xD;
&#xD;
          -  Have malignant tumors of the external auditory canal&#xD;
&#xD;
          -  Have a history of otologic surgery. Surgery performed more than 1 year prior to&#xD;
             Screening/Baseline Visit 1and limited to the tympanic membrane is allowed&#xD;
&#xD;
          -  Have seborrheic dermatitis of the external auditory canal&#xD;
&#xD;
          -  Have a current or prior history of immunosuppressive disorders&#xD;
&#xD;
          -  Have acute or chronic renal insufficiency, hepatitis or diabetes mellitus&#xD;
&#xD;
          -  Be pregnant, nursing or planning a pregnancy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ENT Associates of South Florida</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33426</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Ear, Nose, and Throat Clinic</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Antonio Ear, Nose, and Throat Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Antonio Ear, Nose, and Throat Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ear Institute of Texas</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>July 23, 2009</study_first_submitted>
  <study_first_submitted_qc>July 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 24, 2009</study_first_posted>
  <disposition_first_submitted>September 5, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>September 5, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 6, 2012</disposition_first_posted>
  <last_update_submitted>May 24, 2021</last_update_submitted>
  <last_update_submitted_qc>May 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Otitis</mesh_term>
    <mesh_term>Otitis Externa</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ciprofloxacin</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

